All In Biotech

NDA 208573 · Abbvie

Venclexta

Venetoclax · Oral · BCL-2 Inhibitor

NovelBreakthrough therapyAccelerated approvalPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: May 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Apr 11, 2016

Approved uses

12

Original approval plus efficacy supplements

Registered trials

804

95 Phase 3, 286 recruiting

FAERS reports

62,878

56,926 serious, 17,658 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect May 20, 2026.

VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 ) 1.1 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma VENCLEXTA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). 1.2 Acute Myeloid Leukemia VENCLEXTA is indicated in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Mechanism: Venetoclax is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an anti-apoptotic protein. Overexpression of BCL-2 has been demonstrated in CLL and AML cells where it mediates tumor cell survival and has been associated with resistance to chemotherapeutics. Venetoclax helps restore the process of apoptosis by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM, triggering mitochondrial outer membrane permeabilization and the activation of caspases. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 20, 2026 Supplement 32 · Efficacy OrphanLabelMedication GuideLetter
  • Feb 19, 2026 Supplement 31 · Efficacy OrphanLetterLabel
  • Oct 4, 2021 Supplement 24 · Efficacy OrphanLabelLetter
  • Oct 16, 2020 Supplement 20 · Efficacy · priority review OrphanLabelLetterReview
  • Oct 16, 2020 Supplement 21 · Efficacy · priority review OrphanLabelLetterReview
  • May 15, 2019 Supplement 13 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Nov 21, 2018 Supplement 9 · Efficacy · priority review Breakthrough therapyOrphanLabelLetterReview
  • Sep 7, 2018 Supplement 7 · Efficacy · priority review OrphanLabelLetter
  • Jun 8, 2018 Supplement 4 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
  • Jun 8, 2018 Supplement 5 · Efficacy · priority review OrphanLabelLetter
  • Dec 20, 2017 Supplement 3 · Efficacy · priority review OrphanLabel
  • Apr 11, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyAccelerated approvalOrphanReviewLabelSummary Review
3 products under this application
  • VENCLEXTA · VENETOCLAX 100MG · TABLET, ORAL · Prescription · TE AB
  • VENCLEXTA · VENETOCLAX 10MG · TABLET, ORAL · Prescription · TE AB
  • VENCLEXTA · VENETOCLAX 50MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Venetoclax" as an intervention, any sponsor and status, largest first.

All 804 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death10,347
  • off label use7,028
  • neutropenia3,635
  • febrile neutropenia3,178
  • myelosuppression3,045
  • platelet count decreased2,936
  • pyrexia2,849
  • pneumonia2,733
  • fatigue2,723
  • diarrhoea2,438
  • white blood cell count decreased2,384
  • thrombocytopenia2,281

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20144
201523
2016691
20171,800
20183,586
20195,067
20205,631
20216,270
202211,152
20238,891
20247,506
20257,297
20264,960

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Venclexta (Venetoclax)

2024 spending

$942M

Beneficiaries

21,868

107,871 claims

Per beneficiary

$43,064

$116.48 per unit

View as table
YearSpending
2020$562,138,427
2021$690,959,199
2022$757,567,013
2023$814,653,975
2024$941,720,713

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 431 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.